Neurogene’s Promising Outlook: Strategic Focus on Safety and Efficacy Justifies Buy Rating

H.C. Wainwright analyst Mitchell Kapoor maintained a Buy rating on Neurogene (NGNE – Research Report) today and set a price target of $45.00.

Mitchell Kapoor has given his Buy rating due to a combination of factors that highlight Neurogene’s promising outlook. The company is on track with its timelines and is expected to release positive updated clinical data in the second half of 2025, particularly for its NGN-401 program. The decision to focus on a low-dose version of NGN-401 is seen as a safer approach compared to the high-dose version, which previously led to serious adverse events and a decline in stock value.
Neurogene’s strategy to amend its protocol and enroll patients at a safer dose level of 1E15 vg is viewed favorably, as it addresses safety concerns while maintaining a strong efficacy profile. The differentiation of low-dose NGN-401 is supported by data that suggests a lower risk of life-threatening events compared to high-dose systemic AAV delivery, which has been associated with severe adverse events in other gene therapies. This strategic focus on safety and efficacy, along with anticipated regulatory updates and interim clinical data, underpins Kapoor’s confidence in Neurogene’s potential, justifying the Buy rating.

Kapoor covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, Halozyme, and Summit Therapeutics. According to TipRanks, Kapoor has an average return of -23.3% and a 28.90% success rate on recommended stocks.